The first CAR-T treatment to win approval from the Food and Drug Administration racked up just $12 million in sales last quarter, a reminder that the therapy has a long way to go if it’s ever going to meet Wall Street’s blockbuster expectations.

Analysts expect Novartis’ Kymriah, which costs $475,000 for a one-time dose, to bring in about $159 million this year, according to Evaluate Pharma, meaning the drug maker is going to need to pick up the commercial pace if it hopes to avoid disappointment.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Follow the money,until Medicare and insurers cover the full cost of these treatments,including in hospital costs a slow ramp up was expected.I am sure this will accelerate soon

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy